Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed.

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that ...

though those were tempered a bit this week when the drug stumbled in testing. Having already secured an approval in schizophrenia, Bristol Myers has been trying to show Cobenfy has a range of ...

Bristol Myers Squibb stock dropped Thursday, though the drugmaker beat first-quarter expectations and raised its outlook for ...

A brain drug at the center of a recent $14 billion ... with about half taking Cobenfy and the other half a placebo. Using a well-known, 210-point scale that measures the severity of schizophrenia ...

We chat about the recent bounceback in biotech stocks, disappointing results from Bristol Myers Squibb’s schizophrenia drug Cobenfy, new allegations about entrepreneur Sam Waksal, and more.

The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades.